Здравоохранение Кыргызстана
Zdravoohraneniye Kyrgyzstana
ISSN 1694-8068 (Print)
ISSN 1694-805X (Online)

Молекулярная эпидемиология туберкулеза в Кыргызской Республике

Молекулярная эпидемиология туберкулеза в Кыргызской Республике
Полный текст Full text Толук текст  

Аннотация

Введение. Согласно данным Всемирной Организации Здравоохранения Кыргызская Республика входит в число 18 стран с высокой распространённостью туберкулеза с множественной лекарственной устойчивостью. Молекулярная эпидемиология туберкулёзной инфекции, включая, генетическое разнообразие, маркеры молеку- лярной лекарственной устойчивости и пути передачи штаммов комплекса микобактерий туберкулеза в Кыргыз- ской Республике остаются недостаточно изученными. Секвенирование полного генома было использовано для определения молекулярно-генетической структуры штаммов, циркулирующих на территории страны. Целью ис- следования, явилось описание штаммов комплекса микобактерий туберкулеза на основе секвенирования полного генома как метода молекулярно-генетического исследования. Материалы и методы. В Национальной референс лаборатории Национального Центра Фтизиатрии было проведено секвенирование полного генома под руководством СНРЛ, г. Борстел, Германия. Были протестированы 475 изолятов МБТК за 2018 и 2019 годы. Секвенирование проводили согласно инструкции завода изготовителя на платформе MySeq, Illumina, USA. Протокол MTBSeq был применен для сравнительного геномного анализа и онлайн-инструменты “EvolView and PhyResSe” для выполнения графического представления и скрининга мутаций, опосредующих устойчивость к противотуберкулезным препаратам. Stata/IC версии 16.1 была использована для статистического анализа. Результаты. Используя СПГ, показали, что популяционная структура МБТК в Кыргызской Республике в большинстве своем представлена тремя филогенетическими линиями (L). Эти линии являются L2 (Beijing), L3 (Delhi/CAS) и L4 (Euro-American) в соответствии с классификацией Coll, McNerney и Niemann, Merker. Штаммы L2 были пре- обладающими (74,1%, 352/475), в то время как штаммы L3 и L4 составляли 0,8% (4/475) и 25,1% (119/475) соответственно. Далее мы классифицировали штаммы L2 и L4 на несколько подлиний МБТК (10, 11). Штаммы подлиний Beijing Central Asia (n=225), Beijing Central Asia outbreak (n=75) и Beijing Europe/Russian W148 Outbreak (n=28) являются наиболее распространенными по сравнению со штаммами других подлиний L2 и штаммами подлиний L4. Выводы. Используя СПГ, показали, что туберкулез легких в Кыргызской Республике в основном вызывается штаммами L2 (Beijing). Лекарственная устойчивость также связана со штаммами L2, что подчеркивает важную роль штаммов L2 в эпидемиологии туберкулеза в стране. В целом, наши результаты обеспечивают лучшее понимание молекулярной эпидемиологии туберкулеза в Кыргызской Республике и требуют дополнительных молекулярно-эпидемиологических исследований для выяснения динамики туберкулеза в стране и, следовательно, контроля над ним.

Об авторах

Калмамбетова Гульмира Исмаиловна, к.м.н., зав. национальной референс лаборатории Национального Центра Фтизиатрии Министерства здравоохранения, Бишкек, Кыргызская Республика
Кадыров Абдуллаат Саматович, д.м.н., профессор, директор Национального центра фтизиатрии при Министерстве здравоохранения, Бишкек, Кыргызская Республика
Сыдыкова Мээрбубу Мисировна, лабораторный специалист национальной референс лаборатории Национального центра фтизиатрии при Министерстве здравоохранения, Бишкек, Кыргызская Республика

Мойдунова Нестан Кубанычбековна, к.м.н., ассистент кафедры фтизиатрии КГМА им. И.К.Ахунбаева, Бишкек, Кыргызская Республика

Kalmambetova Gulmira Ismailovna, Ph.D., Head of the National Reference Laboratory of the National Center for Phthisiology of the Ministry of Health, Bishkek, Kyrgyz Republic
Kadyrov Abdullaat Samatovich, MD, Professor, Director of the National Center for Phthisiology at the Ministry of Health, Bishkek, Kyrgyz Republic

Sydykova Meerbubu Misirovna, laboratory specialist, National Reference Laboratory of the National Center for Phthisiology of the Ministry of Health, Bishkek, Kyrgyz Republic
Moidunova Nestan Kubanychbekovna, Ph.D., Assistant, Department of Phthisiology, KSMA named after I.K.Akhunbaeva, Bishkek, Kyrgyz Republic


Калмамбетова Гулмира Исмаиловна, медицина илимдеринин кандидаты,  Республикалык рефенс лаборатория Улуттук фтизиатрия борборунун болум башчысы, Бишкек, Кыргыз Республикасы

Кадыров Абдуллаат Саматович, медицина илимдеринин доктору,  Улуттук фтизиатрия борбору мудуру, Бишкек, Кыргыз Республикасы

Сыдыкова Мээрбубу Мисировна, лабораториялык адис, Республикалык рефенс лаборатория Улуттук фтизиатрия борбору, Бишкек, Кыргыз Республикасы

Мойдунова Нестан Кубанычбекова, медицина илимдеринин кандидаты,  И. К. Ахунбаева атындагы Кыргыз мамлекеттик медициналык академиясынын фтизиатрия кафедрасынын жардамчысы, Бишкек, Кыргыз Республикасы

 

Список литературы

1. World Health Organization. Global Tuberculosis Report 2019. S.l.: WORLD HEALTH ORGANIZATION; 2019.
2. WHO European TB Monitoring and Surveillance Report 2019.
3. Uplekar M, Weil D, Lonnroth K, Jaramillo E, Lienhardt C, Dias HM, et al. WHO’s new End TB Strategy. The Lancet. 2015 May; 385(9979):1799–801.
4. Seung KJ, Keshavjee S, Rich ML. Multidrug-Resistant Tuberculosis and Extensively Drug-Resistant Tuberculosis. Cold Spring Harb Perspect Med. 2015 Sep;5(9): a017863.

5. Shin SS, Asencios L, Yagui M, Yale G, Suárez C, Bayona J, et al. Impact of rapid drug susceptibility testing for tuberculosis: program experience in Lima, Peru. Int J Tuberc Lung Dis. 2017;16(11):1538–43.
6. Eliseev P, Balantcev G, Nikishova E, Gaida A, Bogdanova E, Enarson D, et al. The Impact of a Line Probe Assay Based Diagnostic Algorithm on Time to Treatment Initiation and Treatment Outcomes for Multidrug Resistant TB Patients in Arkhangelsk Region, Russia. PLOS ONE. 2016;13.
7. World Health Organization. Tuberculosis Country profiles: Kyrgyzstan [Internet]. 2019 [cited 2020 Jul 23]. Available from: https://worldhealthorg.shinyapps.io/tb_profiles/_inputs_&lan=%22EN%22&iso2=%22KG%22&main_tabs=%22est_tab%22.
8. The World Bank. The World Bank in the Kyrgyz Republic [Internet]. World Bank. [cited 2020 Apr 22]. Available from:
https://www.worldbank.org/en/country/kyrgyzrepublic/overview.
9. Helmy M, Awad M, Mosa KA. Limited resources of genome sequencing in developing countries: Challenges and solutions. Appl Transl Genomics. 2016 Mar 10;9:15–9.
10. World Health Organization. The use of next-generation sequencing technologies for the detection of mutations associated with drug resistance in Mycobacterium tuberculosis complex: technical guide. 2018.
11. Ulmasov D.J,et al. Multidg-resistant tuberculosis in Uzbekistan: result is of a nationwide survey, 2010 to 2011.Euro Surveill. 2013;18(42):pin:20609.
12. Mokrousov l, et al.Penitentiary population of mycobacterium tuberculosis in Kyrgyzstan:exceptionally high prevalence of the Beijing genotype and its Russia-specific.subtype. Infect Genet. Evol. 2009,9(6):1400-5.
13. Colman RE, Mace A, Seifert M, Hetzel J, Mshaiel H, Suresh A, et al. Whole-genome and targeted sequencing of drug-resistant Mycobacterium tuberculosis on the iSeq100 and MiSeq: A performance, ease-of-use, and cost evaluation. PLoS Med [Internet]2019 Apr 30 [cited 2020 Apr 23];16(4). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6490892/.
14. Rodrigues C, Jani J, Shenai S, Thakkar P, Siddiqi S, Mehta A. Drug susceptibility testing of Mycobacterium tuberculosis against second-line drugs using the Bactec MGIT 960 System. JAMA J Am Med Assoc. 1998 Oct 7;280(13):1200-a-1200.
15. Feuerriegel S, Kohl TA, Utpatel C, Andres S, Maurer FP, Heyckendorf J, et al. Rapid genomic first- and second-line drug resistance prediction from clinical Mycobacterium tuberculosis specimens using Deeplex-MycTB. Eur Respir J [Internet]. 2021 Jan 1 [cited 2021 Feb 19];57(1). Available from: https://erj.ersjournals.com/content/57/1/2001796.
16. Mokrousov l, et al. Molecular snapshot of mycobacterium tuberculosis populations structure and drug resistance in Kyrgyzstan. Tuberculosis (Edinb). 2013.93(5):501-7.
17. Merker M, Kohl TA, Barilar I, Andres S, Fowler PW, Chryssanthou E, et al. Phylogenetically informative mutations in genesimplicated in antibiotic resistance in Mycobacterium tuberculosis complex. Genome Med. 2020 Mar 6;12(1):27.
18. Gröschel MI, Walker TM, van der Werf TS, Lange C, Niemann S, Merker M. Pathogen-based precision medicine for drug-resistant tuberculosis. PLoS Pathog. 2018 Oct;14(10):e1007297.
19. Engstrom A., Antonenca U.,Kabyrov A.,Kalmambetova G et al.Population structure of drug-resistant Mycobacterium tuberculosis in Central Asia.BMC infectious Diseases.2019;19:908 https://doi.org/101186/s12879-019-4480-.
20. IIin A.I.,Kulmanov M.E.,Korotetskiyet I.S. et al. Complete Genome Sequence of Multidrug-Resistant Clinical Isolate Mycobacterium tuberculosis 187.0, Used To Study the Effect of Drug Susceptibility Reversion by the New Medicinal Drug FS-1. Genome announcements, 2015, vol.3(6), e01272-15. CrossRef PubMed.
21. T. Phuong Quan et al. // Evaluation of Whole-Genome Sequencing for Mycobacterial Species Identification and Drug Susceptibility Testing in a Clinical Setting: a Large-Scale Prospective Assessment of Performance against Line Probe Assays and Phenotyping. // J. Clin. Microbiol. February 2018, 56:14 e01480-17; Accepted manuscript posted online 22 November 2017, DOI: 10.1128/JCM.01480-17.
22. Ustinova V. V., Smirnova T. G., Andreevskaya S. N., Andrievskaya I. Yu., Larionova E. E., Chernousova L. N. Genome sequencing of six clinical strains of nontuberculous mycobacteria. Tuberculosis and lung disease, № 12,2018
23. Kozhamkulov U., Kairov U., YerezhepovD., Akhmatova A. Whole-genome sequencing of clinical Mycobacterium tuberculosis isolates with different drug sensitivity profiles. June 2016 Biotechnology Theory and practice. DOI: 10.11134/bop.2.2016.2.

1. World Health Organization. Global Tuberculosis Report 2019. S.l.: WORLD HEALTH ORGANIZATION; 2019.
2. WHO European TB Monitoring and Surveillance Report 2019.
3. Uplekar M, Weil D, Lonnroth K, Jaramillo E, Lienhardt C, Dias HM, et al. WHO’s new End TB Strategy. The Lancet. 2015 May; 385(9979):1799–801.
4. Seung KJ, Keshavjee S, Rich ML. Multidrug-Resistant Tuberculosis and Extensively Drug-Resistant Tuberculosis. Cold Spring Harb Perspect Med. 2015 Sep;5(9): a017863.

5. Shin SS, Asencios L, Yagui M, Yale G, Suárez C, Bayona J, et al. Impact of rapid drug susceptibility testing for tuberculosis: program experience in Lima, Peru. Int J Tuberc Lung Dis. 2017;16(11):1538–43.
6. Eliseev P, Balantcev G, Nikishova E, Gaida A, Bogdanova E, Enarson D, et al. The Impact of a Line Probe Assay Based Diagnostic Algorithm on Time to Treatment Initiation and Treatment Outcomes for Multidrug Resistant TB Patients in Arkhangelsk Region, Russia. PLOS ONE. 2016;13.
7. World Health Organization. Tuberculosis Country profiles: Kyrgyzstan [Internet]. 2019 [cited 2020 Jul 23]. Available from: https://worldhealthorg.shinyapps.io/tb_profiles/_inputs_&lan=%22EN%22&iso2=%22KG%22&main_tabs=%22est_tab%22.
8. The World Bank. The World Bank in the Kyrgyz Republic [Internet]. World Bank. [cited 2020 Apr 22]. Available from:
https://www.worldbank.org/en/country/kyrgyzrepublic/overview.
9. Helmy M, Awad M, Mosa KA. Limited resources of genome sequencing in developing countries: Challenges and solutions. Appl Transl Genomics. 2016 Mar 10;9:15–9.
10. World Health Organization. The use of next-generation sequencing technologies for the detection of mutations associated with drug resistance in Mycobacterium tuberculosis complex: technical guide. 2018.
11. Ulmasov D.J,et al. Multidg-resistant tuberculosis in Uzbekistan: result is of a nationwide survey, 2010 to 2011.Euro Surveill. 2013;18(42):pin:20609.
12. Mokrousov l, et al.Penitentiary population of mycobacterium tuberculosis in Kyrgyzstan:exceptionally high prevalence of the Beijing genotype and its Russia-specific.subtype. Infect Genet. Evol. 2009,9(6):1400-5.
13. Colman RE, Mace A, Seifert M, Hetzel J, Mshaiel H, Suresh A, et al. Whole-genome and targeted sequencing of drug-resistant Mycobacterium tuberculosis on the iSeq100 and MiSeq: A performance, ease-of-use, and cost evaluation. PLoS Med [Internet]2019 Apr 30 [cited 2020 Apr 23];16(4). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6490892/.
14. Rodrigues C, Jani J, Shenai S, Thakkar P, Siddiqi S, Mehta A. Drug susceptibility testing of Mycobacterium tuberculosis against second-line drugs using the Bactec MGIT 960 System. JAMA J Am Med Assoc. 1998 Oct 7;280(13):1200-a-1200.
15. Feuerriegel S, Kohl TA, Utpatel C, Andres S, Maurer FP, Heyckendorf J, et al. Rapid genomic first- and second-line drug resistance prediction from clinical Mycobacterium tuberculosis specimens using Deeplex-MycTB. Eur Respir J [Internet]. 2021 Jan 1 [cited 2021 Feb 19];57(1). Available from: https://erj.ersjournals.com/content/57/1/2001796.
16. Mokrousov l, et al. Molecular snapshot of mycobacterium tuberculosis populations structure and drug resistance in Kyrgyzstan. Tuberculosis (Edinb). 2013.93(5):501-7.
17. Merker M, Kohl TA, Barilar I, Andres S, Fowler PW, Chryssanthou E, et al. Phylogenetically informative mutations in genesimplicated in antibiotic resistance in Mycobacterium tuberculosis complex. Genome Med. 2020 Mar 6;12(1):27.
18. Gröschel MI, Walker TM, van der Werf TS, Lange C, Niemann S, Merker M. Pathogen-based precision medicine for drug-resistant tuberculosis. PLoS Pathog. 2018 Oct;14(10):e1007297.
19. Engstrom A., Antonenca U.,Kabyrov A.,Kalmambetova G et al.Population structure of drug-resistant Mycobacterium tuberculosis in Central Asia.BMC infectious Diseases.2019;19:908 https://doi.org/101186/s12879-019-4480-.
20. IIin A.I.,Kulmanov M.E.,Korotetskiyet I.S. et al. Complete Genome Sequence of Multidrug-Resistant Clinical Isolate Mycobacterium tuberculosis 187.0, Used To Study the Effect of Drug Susceptibility Reversion by the New Medicinal Drug FS-1. Genome announcements, 2015, vol.3(6), e01272-15. CrossRef PubMed.
21. T. Phuong Quan et al. // Evaluation of Whole-Genome Sequencing for Mycobacterial Species Identification and Drug Susceptibility Testing in a Clinical Setting: a Large-Scale Prospective Assessment of Performance against Line Probe Assays and Phenotyping. // J. Clin. Microbiol. February 2018, 56:14 e01480-17; Accepted manuscript posted online 22 November 2017, DOI: 10.1128/JCM.01480-17.
22. Ustinova V. V., Smirnova T. G., Andreevskaya S. N., Andrievskaya I. Yu., Larionova E. E., Chernousova L. N. Genome sequencing of six clinical strains of nontuberculous mycobacteria. Tuberculosis and lung disease, № 12,2018
23. Kozhamkulov U., Kairov U., YerezhepovD., Akhmatova A. Whole-genome sequencing of clinical Mycobacterium tuberculosis isolates with different drug sensitivity profiles. June 2016 Biotechnology Theory and practice. DOI: 10.11134/bop.2.2016.2.

1. World Health Organization. Global Tuberculosis Report 2019. S.l.: WORLD HEALTH ORGANIZATION; 2019.
2. WHO European TB Monitoring and Surveillance Report 2019.
3. Uplekar M, Weil D, Lonnroth K, Jaramillo E, Lienhardt C, Dias HM, et al. WHO’s new End TB Strategy. The Lancet. 2015 May; 385(9979):1799–801.
4. Seung KJ, Keshavjee S, Rich ML. Multidrug-Resistant Tuberculosis and Extensively Drug-Resistant Tuberculosis. Cold Spring Harb Perspect Med. 2015 Sep;5(9): a017863.

5. Shin SS, Asencios L, Yagui M, Yale G, Suárez C, Bayona J, et al. Impact of rapid drug susceptibility testing for tuberculosis: program experience in Lima, Peru. Int J Tuberc Lung Dis. 2017;16(11):1538–43.
6. Eliseev P, Balantcev G, Nikishova E, Gaida A, Bogdanova E, Enarson D, et al. The Impact of a Line Probe Assay Based Diagnostic Algorithm on Time to Treatment Initiation and Treatment Outcomes for Multidrug Resistant TB Patients in Arkhangelsk Region, Russia. PLOS ONE. 2016;13.
7. World Health Organization. Tuberculosis Country profiles: Kyrgyzstan [Internet]. 2019 [cited 2020 Jul 23]. Available from: https://worldhealthorg.shinyapps.io/tb_profiles/_inputs_&lan=%22EN%22&iso2=%22KG%22&main_tabs=%22est_tab%22.
8. The World Bank. The World Bank in the Kyrgyz Republic [Internet]. World Bank. [cited 2020 Apr 22]. Available from:
https://www.worldbank.org/en/country/kyrgyzrepublic/overview.
9. Helmy M, Awad M, Mosa KA. Limited resources of genome sequencing in developing countries: Challenges and solutions. Appl Transl Genomics. 2016 Mar 10;9:15–9.
10. World Health Organization. The use of next-generation sequencing technologies for the detection of mutations associated with drug resistance in Mycobacterium tuberculosis complex: technical guide. 2018.
11. Ulmasov D.J,et al. Multidg-resistant tuberculosis in Uzbekistan: result is of a nationwide survey, 2010 to 2011.Euro Surveill. 2013;18(42):pin:20609.
12. Mokrousov l, et al.Penitentiary population of mycobacterium tuberculosis in Kyrgyzstan:exceptionally high prevalence of the Beijing genotype and its Russia-specific.subtype. Infect Genet. Evol. 2009,9(6):1400-5.
13. Colman RE, Mace A, Seifert M, Hetzel J, Mshaiel H, Suresh A, et al. Whole-genome and targeted sequencing of drug-resistant Mycobacterium tuberculosis on the iSeq100 and MiSeq: A performance, ease-of-use, and cost evaluation. PLoS Med [Internet]2019 Apr 30 [cited 2020 Apr 23];16(4). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6490892/.
14. Rodrigues C, Jani J, Shenai S, Thakkar P, Siddiqi S, Mehta A. Drug susceptibility testing of Mycobacterium tuberculosis against second-line drugs using the Bactec MGIT 960 System. JAMA J Am Med Assoc. 1998 Oct 7;280(13):1200-a-1200.
15. Feuerriegel S, Kohl TA, Utpatel C, Andres S, Maurer FP, Heyckendorf J, et al. Rapid genomic first- and second-line drug resistance prediction from clinical Mycobacterium tuberculosis specimens using Deeplex-MycTB. Eur Respir J [Internet]. 2021 Jan 1 [cited 2021 Feb 19];57(1). Available from: https://erj.ersjournals.com/content/57/1/2001796.
16. Mokrousov l, et al. Molecular snapshot of mycobacterium tuberculosis populations structure and drug resistance in Kyrgyzstan. Tuberculosis (Edinb). 2013.93(5):501-7.
17. Merker M, Kohl TA, Barilar I, Andres S, Fowler PW, Chryssanthou E, et al. Phylogenetically informative mutations in genesimplicated in antibiotic resistance in Mycobacterium tuberculosis complex. Genome Med. 2020 Mar 6;12(1):27.
18. Gröschel MI, Walker TM, van der Werf TS, Lange C, Niemann S, Merker M. Pathogen-based precision medicine for drug-resistant tuberculosis. PLoS Pathog. 2018 Oct;14(10):e1007297.
19. Engstrom A., Antonenca U.,Kabyrov A.,Kalmambetova G et al.Population structure of drug-resistant Mycobacterium tuberculosis in Central Asia.BMC infectious Diseases.2019;19:908 https://doi.org/101186/s12879-019-4480-.
20. IIin A.I.,Kulmanov M.E.,Korotetskiyet I.S. et al. Complete Genome Sequence of Multidrug-Resistant Clinical Isolate Mycobacterium tuberculosis 187.0, Used To Study the Effect of Drug Susceptibility Reversion by the New Medicinal Drug FS-1. Genome announcements, 2015, vol.3(6), e01272-15. CrossRef PubMed.
21. T. Phuong Quan et al. // Evaluation of Whole-Genome Sequencing for Mycobacterial Species Identification and Drug Susceptibility Testing in a Clinical Setting: a Large-Scale Prospective Assessment of Performance against Line Probe Assays and Phenotyping. // J. Clin. Microbiol. February 2018, 56:14 e01480-17; Accepted manuscript posted online 22 November 2017, DOI: 10.1128/JCM.01480-17.
22. Ustinova V. V., Smirnova T. G., Andreevskaya S. N., Andrievskaya I. Yu., Larionova E. E., Chernousova L. N. Genome sequencing of six clinical strains of nontuberculous mycobacteria. Tuberculosis and lung disease, № 12,2018
23. Kozhamkulov U., Kairov U., YerezhepovD., Akhmatova A. Whole-genome sequencing of clinical Mycobacterium tuberculosis isolates with different drug sensitivity profiles. June 2016 Biotechnology Theory and practice. DOI: 10.11134/bop.2.2016.2.

Для цитирования

Калмамбетова Г.И., Кадыров А.С., Сыдыкова М.М., Мойдунова Н.К. Молекулярная эпидемиология туберкулеза в Кыргызской Республике. Здравоохранение Кыргызстана 2022, № 2, с.86- 91. https://dx.doi.org/10.51350/zdravkg2022621186

For citation

Kalmambetova G.I.,Kadyrov A.S.,Sydykova M.M.,Moidunova N.K. Molecular epidemiology of tuberculosis in the Kyrgyz Republic. Health care of Kyrgyzstan 2022, No. 2, pp. 86-91. https://dx.doi.org/10.51350/zdravkg2022621186

Цитата үчүн

Калмамбетова Г.И., Кадыров А.С., Сыдыкова М.М., Мойдунова Н.К.Кыргыз Республикасындагы кургак учуктун молекулярдык эпидемиологиясы. Кыргызстандын саламаттык сактоо 2022, no 2, б. 86-91. https://dx.doi.org/10.51350/zdravkg2022621186

Авторы Калманбетова Г.И., Кадыров А.С., Сыдыкова М.М., Мойдунова Н.К.
Ссылка doi.org https://doi.org/10.51350/zdravkg2022621186
Страницы 86-91
Ключевые слова туберкулез, молекулярно-генетические методы, секвенирование полного генома, штамм линии L2 (Beijing)
Русский
Об авторах

Калмамбетова Гульмира Исмаиловна, к.м.н., зав. национальной референс лаборатории Национального Центра Фтизиатрии Министерства здравоохранения, Бишкек, Кыргызская Республика
Кадыров Абдуллаат Саматович, д.м.н., профессор, директор Национального центра фтизиатрии при Министерстве здравоохранения, Бишкек, Кыргызская Республика
Сыдыкова Мээрбубу Мисировна, лабораторный специалист национальной референс лаборатории Национального центра фтизиатрии при Министерстве здравоохранения, Бишкек, Кыргызская Республика

Мойдунова Нестан Кубанычбековна, к.м.н., ассистент кафедры фтизиатрии КГМА им. И.К.Ахунбаева, Бишкек, Кыргызская Республика

Полный текст

PDF (RUS)

Список литературы

1. World Health Organization. Global Tuberculosis Report 2019. S.l.: WORLD HEALTH ORGANIZATION; 2019.
2. WHO European TB Monitoring and Surveillance Report 2019.
3. Uplekar M, Weil D, Lonnroth K, Jaramillo E, Lienhardt C, Dias HM, et al. WHO’s new End TB Strategy. The Lancet. 2015 May; 385(9979):1799–801.
4. Seung KJ, Keshavjee S, Rich ML. Multidrug-Resistant Tuberculosis and Extensively Drug-Resistant Tuberculosis. Cold Spring Harb Perspect Med. 2015 Sep;5(9): a017863.

5. Shin SS, Asencios L, Yagui M, Yale G, Suárez C, Bayona J, et al. Impact of rapid drug susceptibility testing for tuberculosis: program experience in Lima, Peru. Int J Tuberc Lung Dis. 2017;16(11):1538–43.
6. Eliseev P, Balantcev G, Nikishova E, Gaida A, Bogdanova E, Enarson D, et al. The Impact of a Line Probe Assay Based Diagnostic Algorithm on Time to Treatment Initiation and Treatment Outcomes for Multidrug Resistant TB Patients in Arkhangelsk Region, Russia. PLOS ONE. 2016;13.
7. World Health Organization. Tuberculosis Country profiles: Kyrgyzstan [Internet]. 2019 [cited 2020 Jul 23]. Available from: https://worldhealthorg.shinyapps.io/tb_profiles/_inputs_&lan=%22EN%22&iso2=%22KG%22&main_tabs=%22est_tab%22.
8. The World Bank. The World Bank in the Kyrgyz Republic [Internet]. World Bank. [cited 2020 Apr 22]. Available from:
https://www.worldbank.org/en/country/kyrgyzrepublic/overview.
9. Helmy M, Awad M, Mosa KA. Limited resources of genome sequencing in developing countries: Challenges and solutions. Appl Transl Genomics. 2016 Mar 10;9:15–9.
10. World Health Organization. The use of next-generation sequencing technologies for the detection of mutations associated with drug resistance in Mycobacterium tuberculosis complex: technical guide. 2018.
11. Ulmasov D.J,et al. Multidg-resistant tuberculosis in Uzbekistan: result is of a nationwide survey, 2010 to 2011.Euro Surveill. 2013;18(42):pin:20609.
12. Mokrousov l, et al.Penitentiary population of mycobacterium tuberculosis in Kyrgyzstan:exceptionally high prevalence of the Beijing genotype and its Russia-specific.subtype. Infect Genet. Evol. 2009,9(6):1400-5.
13. Colman RE, Mace A, Seifert M, Hetzel J, Mshaiel H, Suresh A, et al. Whole-genome and targeted sequencing of drug-resistant Mycobacterium tuberculosis on the iSeq100 and MiSeq: A performance, ease-of-use, and cost evaluation. PLoS Med [Internet]2019 Apr 30 [cited 2020 Apr 23];16(4). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6490892/.
14. Rodrigues C, Jani J, Shenai S, Thakkar P, Siddiqi S, Mehta A. Drug susceptibility testing of Mycobacterium tuberculosis against second-line drugs using the Bactec MGIT 960 System. JAMA J Am Med Assoc. 1998 Oct 7;280(13):1200-a-1200.
15. Feuerriegel S, Kohl TA, Utpatel C, Andres S, Maurer FP, Heyckendorf J, et al. Rapid genomic first- and second-line drug resistance prediction from clinical Mycobacterium tuberculosis specimens using Deeplex-MycTB. Eur Respir J [Internet]. 2021 Jan 1 [cited 2021 Feb 19];57(1). Available from: https://erj.ersjournals.com/content/57/1/2001796.
16. Mokrousov l, et al. Molecular snapshot of mycobacterium tuberculosis populations structure and drug resistance in Kyrgyzstan. Tuberculosis (Edinb). 2013.93(5):501-7.
17. Merker M, Kohl TA, Barilar I, Andres S, Fowler PW, Chryssanthou E, et al. Phylogenetically informative mutations in genesimplicated in antibiotic resistance in Mycobacterium tuberculosis complex. Genome Med. 2020 Mar 6;12(1):27.
18. Gröschel MI, Walker TM, van der Werf TS, Lange C, Niemann S, Merker M. Pathogen-based precision medicine for drug-resistant tuberculosis. PLoS Pathog. 2018 Oct;14(10):e1007297.
19. Engstrom A., Antonenca U.,Kabyrov A.,Kalmambetova G et al.Population structure of drug-resistant Mycobacterium tuberculosis in Central Asia.BMC infectious Diseases.2019;19:908 https://doi.org/101186/s12879-019-4480-.
20. IIin A.I.,Kulmanov M.E.,Korotetskiyet I.S. et al. Complete Genome Sequence of Multidrug-Resistant Clinical Isolate Mycobacterium tuberculosis 187.0, Used To Study the Effect of Drug Susceptibility Reversion by the New Medicinal Drug FS-1. Genome announcements, 2015, vol.3(6), e01272-15. CrossRef PubMed.
21. T. Phuong Quan et al. // Evaluation of Whole-Genome Sequencing for Mycobacterial Species Identification and Drug Susceptibility Testing in a Clinical Setting: a Large-Scale Prospective Assessment of Performance against Line Probe Assays and Phenotyping. // J. Clin. Microbiol. February 2018, 56:14 e01480-17; Accepted manuscript posted online 22 November 2017, DOI: 10.1128/JCM.01480-17.
22. Ustinova V. V., Smirnova T. G., Andreevskaya S. N., Andrievskaya I. Yu., Larionova E. E., Chernousova L. N. Genome sequencing of six clinical strains of nontuberculous mycobacteria. Tuberculosis and lung disease, № 12,2018
23. Kozhamkulov U., Kairov U., YerezhepovD., Akhmatova A. Whole-genome sequencing of clinical Mycobacterium tuberculosis isolates with different drug sensitivity profiles. June 2016 Biotechnology Theory and practice. DOI: 10.11134/bop.2.2016.2.

Для цитирования

Калмамбетова Г.И., Кадыров А.С., Сыдыкова М.М., Мойдунова Н.К. Молекулярная эпидемиология туберкулеза в Кыргызской Республике. Здравоохранение Кыргызстана 2022, № 2, с.86- 91. https://dx.doi.org/10.51350/zdravkg2022621186

Английский
About authors

Kalmambetova Gulmira Ismailovna, Ph.D., Head of the National Reference Laboratory of the National Center for Phthisiology of the Ministry of Health, Bishkek, Kyrgyz Republic
Kadyrov Abdullaat Samatovich, MD, Professor, Director of the National Center for Phthisiology at the Ministry of Health, Bishkek, Kyrgyz Republic

Sydykova Meerbubu Misirovna, laboratory specialist, National Reference Laboratory of the National Center for Phthisiology of the Ministry of Health, Bishkek, Kyrgyz Republic
Moidunova Nestan Kubanychbekovna, Ph.D., Assistant, Department of Phthisiology, KSMA named after I.K.Akhunbaeva, Bishkek, Kyrgyz Republic


Full text

PDF (RUS)

References

1. World Health Organization. Global Tuberculosis Report 2019. S.l.: WORLD HEALTH ORGANIZATION; 2019.
2. WHO European TB Monitoring and Surveillance Report 2019.
3. Uplekar M, Weil D, Lonnroth K, Jaramillo E, Lienhardt C, Dias HM, et al. WHO’s new End TB Strategy. The Lancet. 2015 May; 385(9979):1799–801.
4. Seung KJ, Keshavjee S, Rich ML. Multidrug-Resistant Tuberculosis and Extensively Drug-Resistant Tuberculosis. Cold Spring Harb Perspect Med. 2015 Sep;5(9): a017863.

5. Shin SS, Asencios L, Yagui M, Yale G, Suárez C, Bayona J, et al. Impact of rapid drug susceptibility testing for tuberculosis: program experience in Lima, Peru. Int J Tuberc Lung Dis. 2017;16(11):1538–43.
6. Eliseev P, Balantcev G, Nikishova E, Gaida A, Bogdanova E, Enarson D, et al. The Impact of a Line Probe Assay Based Diagnostic Algorithm on Time to Treatment Initiation and Treatment Outcomes for Multidrug Resistant TB Patients in Arkhangelsk Region, Russia. PLOS ONE. 2016;13.
7. World Health Organization. Tuberculosis Country profiles: Kyrgyzstan [Internet]. 2019 [cited 2020 Jul 23]. Available from: https://worldhealthorg.shinyapps.io/tb_profiles/_inputs_&lan=%22EN%22&iso2=%22KG%22&main_tabs=%22est_tab%22.
8. The World Bank. The World Bank in the Kyrgyz Republic [Internet]. World Bank. [cited 2020 Apr 22]. Available from:
https://www.worldbank.org/en/country/kyrgyzrepublic/overview.
9. Helmy M, Awad M, Mosa KA. Limited resources of genome sequencing in developing countries: Challenges and solutions. Appl Transl Genomics. 2016 Mar 10;9:15–9.
10. World Health Organization. The use of next-generation sequencing technologies for the detection of mutations associated with drug resistance in Mycobacterium tuberculosis complex: technical guide. 2018.
11. Ulmasov D.J,et al. Multidg-resistant tuberculosis in Uzbekistan: result is of a nationwide survey, 2010 to 2011.Euro Surveill. 2013;18(42):pin:20609.
12. Mokrousov l, et al.Penitentiary population of mycobacterium tuberculosis in Kyrgyzstan:exceptionally high prevalence of the Beijing genotype and its Russia-specific.subtype. Infect Genet. Evol. 2009,9(6):1400-5.
13. Colman RE, Mace A, Seifert M, Hetzel J, Mshaiel H, Suresh A, et al. Whole-genome and targeted sequencing of drug-resistant Mycobacterium tuberculosis on the iSeq100 and MiSeq: A performance, ease-of-use, and cost evaluation. PLoS Med [Internet]2019 Apr 30 [cited 2020 Apr 23];16(4). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6490892/.
14. Rodrigues C, Jani J, Shenai S, Thakkar P, Siddiqi S, Mehta A. Drug susceptibility testing of Mycobacterium tuberculosis against second-line drugs using the Bactec MGIT 960 System. JAMA J Am Med Assoc. 1998 Oct 7;280(13):1200-a-1200.
15. Feuerriegel S, Kohl TA, Utpatel C, Andres S, Maurer FP, Heyckendorf J, et al. Rapid genomic first- and second-line drug resistance prediction from clinical Mycobacterium tuberculosis specimens using Deeplex-MycTB. Eur Respir J [Internet]. 2021 Jan 1 [cited 2021 Feb 19];57(1). Available from: https://erj.ersjournals.com/content/57/1/2001796.
16. Mokrousov l, et al. Molecular snapshot of mycobacterium tuberculosis populations structure and drug resistance in Kyrgyzstan. Tuberculosis (Edinb). 2013.93(5):501-7.
17. Merker M, Kohl TA, Barilar I, Andres S, Fowler PW, Chryssanthou E, et al. Phylogenetically informative mutations in genesimplicated in antibiotic resistance in Mycobacterium tuberculosis complex. Genome Med. 2020 Mar 6;12(1):27.
18. Gröschel MI, Walker TM, van der Werf TS, Lange C, Niemann S, Merker M. Pathogen-based precision medicine for drug-resistant tuberculosis. PLoS Pathog. 2018 Oct;14(10):e1007297.
19. Engstrom A., Antonenca U.,Kabyrov A.,Kalmambetova G et al.Population structure of drug-resistant Mycobacterium tuberculosis in Central Asia.BMC infectious Diseases.2019;19:908 https://doi.org/101186/s12879-019-4480-.
20. IIin A.I.,Kulmanov M.E.,Korotetskiyet I.S. et al. Complete Genome Sequence of Multidrug-Resistant Clinical Isolate Mycobacterium tuberculosis 187.0, Used To Study the Effect of Drug Susceptibility Reversion by the New Medicinal Drug FS-1. Genome announcements, 2015, vol.3(6), e01272-15. CrossRef PubMed.
21. T. Phuong Quan et al. // Evaluation of Whole-Genome Sequencing for Mycobacterial Species Identification and Drug Susceptibility Testing in a Clinical Setting: a Large-Scale Prospective Assessment of Performance against Line Probe Assays and Phenotyping. // J. Clin. Microbiol. February 2018, 56:14 e01480-17; Accepted manuscript posted online 22 November 2017, DOI: 10.1128/JCM.01480-17.
22. Ustinova V. V., Smirnova T. G., Andreevskaya S. N., Andrievskaya I. Yu., Larionova E. E., Chernousova L. N. Genome sequencing of six clinical strains of nontuberculous mycobacteria. Tuberculosis and lung disease, № 12,2018
23. Kozhamkulov U., Kairov U., YerezhepovD., Akhmatova A. Whole-genome sequencing of clinical Mycobacterium tuberculosis isolates with different drug sensitivity profiles. June 2016 Biotechnology Theory and practice. DOI: 10.11134/bop.2.2016.2.

For citation

Kalmambetova G.I.,Kadyrov A.S.,Sydykova M.M.,Moidunova N.K. Molecular epidemiology of tuberculosis in the Kyrgyz Republic. Health care of Kyrgyzstan 2022, No. 2, pp. 86-91. https://dx.doi.org/10.51350/zdravkg2022621186

Кыргызский
Авторлор жөнүндө

Калмамбетова Гулмира Исмаиловна, медицина илимдеринин кандидаты,  Республикалык рефенс лаборатория Улуттук фтизиатрия борборунун болум башчысы, Бишкек, Кыргыз Республикасы

Кадыров Абдуллаат Саматович, медицина илимдеринин доктору,  Улуттук фтизиатрия борбору мудуру, Бишкек, Кыргыз Республикасы

Сыдыкова Мээрбубу Мисировна, лабораториялык адис, Республикалык рефенс лаборатория Улуттук фтизиатрия борбору, Бишкек, Кыргыз Республикасы

Мойдунова Нестан Кубанычбекова, медицина илимдеринин кандидаты,  И. К. Ахунбаева атындагы Кыргыз мамлекеттик медициналык академиясынын фтизиатрия кафедрасынын жардамчысы, Бишкек, Кыргыз Республикасы

 

Толук текст

PDF (RUS)

Шилтемелер

1. World Health Organization. Global Tuberculosis Report 2019. S.l.: WORLD HEALTH ORGANIZATION; 2019.
2. WHO European TB Monitoring and Surveillance Report 2019.
3. Uplekar M, Weil D, Lonnroth K, Jaramillo E, Lienhardt C, Dias HM, et al. WHO’s new End TB Strategy. The Lancet. 2015 May; 385(9979):1799–801.
4. Seung KJ, Keshavjee S, Rich ML. Multidrug-Resistant Tuberculosis and Extensively Drug-Resistant Tuberculosis. Cold Spring Harb Perspect Med. 2015 Sep;5(9): a017863.

5. Shin SS, Asencios L, Yagui M, Yale G, Suárez C, Bayona J, et al. Impact of rapid drug susceptibility testing for tuberculosis: program experience in Lima, Peru. Int J Tuberc Lung Dis. 2017;16(11):1538–43.
6. Eliseev P, Balantcev G, Nikishova E, Gaida A, Bogdanova E, Enarson D, et al. The Impact of a Line Probe Assay Based Diagnostic Algorithm on Time to Treatment Initiation and Treatment Outcomes for Multidrug Resistant TB Patients in Arkhangelsk Region, Russia. PLOS ONE. 2016;13.
7. World Health Organization. Tuberculosis Country profiles: Kyrgyzstan [Internet]. 2019 [cited 2020 Jul 23]. Available from: https://worldhealthorg.shinyapps.io/tb_profiles/_inputs_&lan=%22EN%22&iso2=%22KG%22&main_tabs=%22est_tab%22.
8. The World Bank. The World Bank in the Kyrgyz Republic [Internet]. World Bank. [cited 2020 Apr 22]. Available from:
https://www.worldbank.org/en/country/kyrgyzrepublic/overview.
9. Helmy M, Awad M, Mosa KA. Limited resources of genome sequencing in developing countries: Challenges and solutions. Appl Transl Genomics. 2016 Mar 10;9:15–9.
10. World Health Organization. The use of next-generation sequencing technologies for the detection of mutations associated with drug resistance in Mycobacterium tuberculosis complex: technical guide. 2018.
11. Ulmasov D.J,et al. Multidg-resistant tuberculosis in Uzbekistan: result is of a nationwide survey, 2010 to 2011.Euro Surveill. 2013;18(42):pin:20609.
12. Mokrousov l, et al.Penitentiary population of mycobacterium tuberculosis in Kyrgyzstan:exceptionally high prevalence of the Beijing genotype and its Russia-specific.subtype. Infect Genet. Evol. 2009,9(6):1400-5.
13. Colman RE, Mace A, Seifert M, Hetzel J, Mshaiel H, Suresh A, et al. Whole-genome and targeted sequencing of drug-resistant Mycobacterium tuberculosis on the iSeq100 and MiSeq: A performance, ease-of-use, and cost evaluation. PLoS Med [Internet]2019 Apr 30 [cited 2020 Apr 23];16(4). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6490892/.
14. Rodrigues C, Jani J, Shenai S, Thakkar P, Siddiqi S, Mehta A. Drug susceptibility testing of Mycobacterium tuberculosis against second-line drugs using the Bactec MGIT 960 System. JAMA J Am Med Assoc. 1998 Oct 7;280(13):1200-a-1200.
15. Feuerriegel S, Kohl TA, Utpatel C, Andres S, Maurer FP, Heyckendorf J, et al. Rapid genomic first- and second-line drug resistance prediction from clinical Mycobacterium tuberculosis specimens using Deeplex-MycTB. Eur Respir J [Internet]. 2021 Jan 1 [cited 2021 Feb 19];57(1). Available from: https://erj.ersjournals.com/content/57/1/2001796.
16. Mokrousov l, et al. Molecular snapshot of mycobacterium tuberculosis populations structure and drug resistance in Kyrgyzstan. Tuberculosis (Edinb). 2013.93(5):501-7.
17. Merker M, Kohl TA, Barilar I, Andres S, Fowler PW, Chryssanthou E, et al. Phylogenetically informative mutations in genesimplicated in antibiotic resistance in Mycobacterium tuberculosis complex. Genome Med. 2020 Mar 6;12(1):27.
18. Gröschel MI, Walker TM, van der Werf TS, Lange C, Niemann S, Merker M. Pathogen-based precision medicine for drug-resistant tuberculosis. PLoS Pathog. 2018 Oct;14(10):e1007297.
19. Engstrom A., Antonenca U.,Kabyrov A.,Kalmambetova G et al.Population structure of drug-resistant Mycobacterium tuberculosis in Central Asia.BMC infectious Diseases.2019;19:908 https://doi.org/101186/s12879-019-4480-.
20. IIin A.I.,Kulmanov M.E.,Korotetskiyet I.S. et al. Complete Genome Sequence of Multidrug-Resistant Clinical Isolate Mycobacterium tuberculosis 187.0, Used To Study the Effect of Drug Susceptibility Reversion by the New Medicinal Drug FS-1. Genome announcements, 2015, vol.3(6), e01272-15. CrossRef PubMed.
21. T. Phuong Quan et al. // Evaluation of Whole-Genome Sequencing for Mycobacterial Species Identification and Drug Susceptibility Testing in a Clinical Setting: a Large-Scale Prospective Assessment of Performance against Line Probe Assays and Phenotyping. // J. Clin. Microbiol. February 2018, 56:14 e01480-17; Accepted manuscript posted online 22 November 2017, DOI: 10.1128/JCM.01480-17.
22. Ustinova V. V., Smirnova T. G., Andreevskaya S. N., Andrievskaya I. Yu., Larionova E. E., Chernousova L. N. Genome sequencing of six clinical strains of nontuberculous mycobacteria. Tuberculosis and lung disease, № 12,2018
23. Kozhamkulov U., Kairov U., YerezhepovD., Akhmatova A. Whole-genome sequencing of clinical Mycobacterium tuberculosis isolates with different drug sensitivity profiles. June 2016 Biotechnology Theory and practice. DOI: 10.11134/bop.2.2016.2.

Цитата үчүн

Калмамбетова Г.И., Кадыров А.С., Сыдыкова М.М., Мойдунова Н.К.Кыргыз Республикасындагы кургак учуктун молекулярдык эпидемиологиясы. Кыргызстандын саламаттык сактоо 2022, no 2, б. 86-91. https://dx.doi.org/10.51350/zdravkg2022621186

Просмотров: 117
Copyright MAXXmarketing GmbH
JoomShopping Download & Support
ISSN 1694-8068 (Print)
ISSN 1694-805X (Online)